What's Happening?
During a recent FDA PreCheck meeting, pharmaceutical industry representatives advocated for extending support to existing manufacturing facilities. The FDA's PreCheck program aims to facilitate the construction
of new sites, but industry leaders argue that activating idle capacity in existing plants is a faster and more cost-effective solution to increase domestic drug production. A survey revealed that many U.S. pharmaceutical sites are underutilized, with significant potential to boost production without building new facilities.
Why It's Important?
The push to include existing facilities in the FDA's PreCheck program highlights the need for efficient solutions to address drug shortages and reduce reliance on imports. By utilizing idle capacity, the pharmaceutical industry can quickly ramp up production, ensuring a stable supply of essential medications. This approach not only supports domestic manufacturing but also aligns with broader efforts to enhance the resilience of the U.S. healthcare system. The industry's call for regulatory support reflects the ongoing challenges in balancing innovation with practical solutions for drug production.
